Dive Brief: Intellia Therapeutics will stop work on one of its principal drug research programs and lay off more than one-quarter of its staff in a restructuring meant to prioritize resources around its two most advanced experimental medicines. The discontinued...
Vertex Pharmaceuticals is aiming to broaden its capabilities in rare blood disease treatments by teaming up with Orna Therapeutics’ ReNAgade platform to develop next-generation gene therapies for sickle cell disease (SCD) and transfusion-dependent beta...
Credit: Unsplash/CC0 Public Domain A collaborative effort between investigators at the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH) demonstrates the potential of precise...
Last week, Eli Lilly opened the doors of its new research center in Boston, largely focused on genetic therapies. While the Indianapolis-based drugmaker’s $875 billion valuation largely stems from its diabetes and weight loss medicines, CSO Dan Skovronsky said that...
The EveryLife Foundation for Rare Diseases commends the Food and Drug Administration (FDA) on today’s announcement of its intention to create a Rare Disease Innovation Hub. Co-chaired by CDER Director, Dr. Peter Marks, and CBER Director, Dr. Patrizia Cavazzoni,...
